NeoPath AutoPap Primary Screener Use Would Reduce Labor Costs 25%
This article was originally published in The Gray Sheet
Use of NeoPath's AutoPap automated primary Pap smear screener would be able to cut laboratory labor costs by 25% and allow for a 33% increase in productivity, NeoPath President and CEO Alan Nelson told analysts during a May 8 teleconference.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.